RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cost-Effectiveness Analysis of Tenofovir/Emtricitabine and Abacavir/Lamivudine in Combination with Efavirenz Or Atazanavir/Ritonavir for Treatment-Naive Adults with Hiv-1 Infection in the United Kingdom
Wilkins, E., Fisher, M., Brogan, A., & Talbird, S. (2014). Cost-Effectiveness Analysis of Tenofovir/Emtricitabine and Abacavir/Lamivudine in Combination with Efavirenz Or Atazanavir/Ritonavir for Treatment-Naive Adults with Hiv-1 Infection in the United Kingdom. Value in Health, 17(3), A276-A276.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.